Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
SurvivorNet on MSN
Cancer patients are living longer — a closer look at the treatments driving this progress
New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...
Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology ...
Scientists in southern China have developed a new strategy to fight cancer by forcing tumor cells to "expose themselves" to ...
The result is one molecule that can be both a checkpoint degrader and a cancer vaccine ( Nature 2026, DOI: 10.1038/s41586-025 ...
ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...
The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer ...
Detailed price information for Nurix Therapeutics Inc (NRIX-Q) from The Globe and Mail including charting and trades.
Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...
Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback